Table 2.
Sociodemographic Information for Autoimmune and Depression Cases and Controls
| Pop. Prev. |
Count |
UKB Prev. |
Age, Years, Mean (SD) |
Female |
TDI, Mean (SD) |
Current Smoker |
BMI, kg/m2, Mean (SD) |
Count |
UKB Prev. |
Age, Years, Mean (SD) |
Female |
TDI, Mean (SD) |
Current Smoker |
BMI, kg/m2, Mean (SD) |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Possible |
Probable |
||||||||||||||
| Autoimmune Diseases | |||||||||||||||
| Circulatory System | |||||||||||||||
| Pernicious anemia | 0.10% | 1555 | 0.48% | 58.9 (7.61) | 71% | −0.85 (3.19) | 13% | 28.0 (5.55) | 423 | 0.13% | 60.1 (7.19) | 72% | −0.99 (3.23) | 12% | 28.5 (5.34) |
| Endocrine System | |||||||||||||||
| Autoimmune thyroid disease | 2.00% | 859 | 0.26% | 56.8 (7.75) | 85% | −1.11 (3.05) | 15% | 27.4 (5.11) | 607 | 0.19% | 57.0 (7.64) | 86% | −1.06 (3.03) | 16% | 27.8 (5.21) |
| Type 1 diabetes | 0.30% | 2751 | 0.84% | 58.3 (7.80) | 42% | −0.46 (3.39) | 13% | 30.1 (6.08) | 2292 | 0.70% | 58.0 (7.85) | 43% | −0.50 (3.39) | 12% | 29.9 (6.07) |
| Nervous System | |||||||||||||||
| Multiple sclerosis | 0.10% | 1683 | 0.52% | 55.4 (7.52) | 73% | −1.45 (3.01) | 16% | 26.9 (5.08) | 1154 | 0.35% | 55.5 (7.45) | 73% | −1.33 (3.06) | 17% | 26.9 (5.27) |
| Myasthenia gravis | 0.02% | 234 | 0.07% | 59.2 (7.39) | 56% | −0.94 (3.27) | 11% | 29.0 (5.44) | 147 | 0.05% | 60.1 (7.09) | 48% | −1.06 (3.32) | 12% | 29.3 (5.18) |
| Digestive System | |||||||||||||||
| Celiac | 1.00% | 2364 | 0.72% | 57.8 (7.79) | 67% | −1.49 (2.99) | 7% | 25.8 (4.57) | 1260 | 0.39% | 58.4 (7.66) | 68% | −1.42 (3.03) | 7% | 25.8 (4.60) |
| Inflammatory bowel disease | 0.50% | 5105 | 1.55% | 57.4 (7.92) | 51% | −1.27 (3.10) | 10% | 27.3 (4.70) | 3538 | 1.08% | 57.3 (7.98) | 50% | −1.28 (3.07) | 9% | 27.2 (4.63) |
| Skin | |||||||||||||||
| Psoriasis | 2.00% | 5459 | 1.66% | 56.8 (8.01) | 46% | −1.05 (3.22) | 15% | 28.4 (5.17) | 2759 | 0.84% | 57.1 (8.04) | 42% | −0.90 (3.28) | 16% | 28.7 (5.26) |
| Musculoskeletal System and Connective Tissue | |||||||||||||||
| Ankylosing spondylitis | 0.55% | 1344 | 0.41% | 57.9 (7.47) | 38% | −1.02 (3.21) | 13% | 27.8 (4.80) | 413 | 0.13% | 57.4 (7.57) | 26% | −1.06 (3.22) | 12% | 27.9 (4.85) |
| Polymyalgia rheumatica/GCA | 0.85% | 1627 | 0.50% | 63.1 (5.16) | 67% | −1.70 (2.79) | 9% | 28.3 (5.08) | 898 | 0.28% | 63.7 (4.58) | 68% | −1.67 (2.75) | 9% | 28.4 (5.24) |
| Psoriatic arthritis | 0.50% | 1107 | 0.34% | 56.6 (7.48) | 50% | −1.16 (3.18) | 11% | 29.0 (5.43) | 779 | 0.24% | 56.6 (7.52) | 51% | −1.06 (3.23) | 11% | 29.3 (5.59) |
| Rheumatoid arthritis | 1.00% | 6360 | 1.92% | 59.5 (7.06) | 67% | −0.91 (3.29) | 13% | 28.5 (5.53) | 3451 | 1.05% | 59.6 (7.01) | 70% | −1.08 (3.18) | 12% | 28.2 (5.50) |
| Sjögren syndrome | 0.70% | 647 | 0.20% | 59.3 (7.10) | 90% | −1.20 (3.03) | 6% | 27.1 (5.72) | 389 | 0.12% | 59.2 (7.26) | 89% | −1.19 (3.10) | 7% | 27.0 (5.55) |
| Systemic lupus erythematosus | 0.10% | 624 | 0.19% | 56.7 (8.18) | 84% | −1.02 (3.21) | 14% | 27.3 (5.65) | 362 | 0.11% | 56.6 (8.00) | 86% | −0.99 (3.15) | 14% | 27.3 (5.82) |
| Any Autoimmune Disease | NA | 28,479 | 8.08% | 58.1 (7.73) | 58% | −1.11 (3.17) | 12% | 27.9 (5.28) | 16,824 | 4.94% | 58.1 (7.73) | 57% | −1.10 (3.17) | 12% | 28.0 (5.34) |
| Autoimmune Controls |
NA |
324,074 |
NA |
56.4 (8.06) |
52% |
−1.50 (2.98) |
10% |
27.2 (4.64) |
324,074 |
NA |
56.4 (8.06) |
52% |
−1.50 (2.98) |
10% |
27.2 (4.64) |
| Depression |
Any |
Stringent |
|||||||||||||
| Depression Cases | 15% | 65,075 | 21.86% | 55.4 (7.86) | 67% | −1.09 (3.14) | 13% | 27.8 (5.32) | 14,625 | 5.92% | 56.1 (7.88) | 67% | −0.58 (3.35) | 19% | 28.9 (5.77) |
| Depression Controls | NA | 232,552 | NA | 57.1 (8.10) | 47% | −1.65 (2.89) | 9% | 27.2 (4.53) | 232,552 | NA | 57.1 (8.10) | 47% | −1.65 (2.89) | 9% | 27.2 (4.53) |
Negative scores on the TDI indicate less deprivation.
BMI, body mass index; GCA, giant cell arteritis; NA, not applicable; Pop. Prev., population prevalence estimate; TDI, Townsend deprivation index; UKB Prev., prevalence of cases in the UK Biobank as a proportion of autoimmune/depression controls.